X4 Pharmaceuticals (NASDAQ:XFOR) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) posted its quarterly earnings data on Wednesday. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02, Zacks reports. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.

X4 Pharmaceuticals Trading Up 2.2%

XFOR traded up $0.07 during trading hours on Wednesday, reaching $3.24. 536,564 shares of the company’s stock traded hands, compared to its average volume of 641,872. X4 Pharmaceuticals has a 52-week low of $2.43 and a 52-week high of $4.83. The firm has a market capitalization of $321.25 million, a PE ratio of -2.70 and a beta of 0.47. The firm has a 50-day moving average price of $3.30 and a 200 day moving average price of $3.79. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49.

Insider Transactions at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, President John Volpone sold 24,576 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $109,117.44. Following the completion of the sale, the president directly owned 265,305 shares of the company’s stock, valued at $1,177,954.20. The trade was a 8.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO David Kirske sold 11,767 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $2.86, for a total transaction of $33,653.62. Following the completion of the sale, the chief financial officer directly owned 155,983 shares of the company’s stock, valued at approximately $446,111.38. This trade represents a 7.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 83,779 shares of company stock worth $353,387. Insiders own 1.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on XFOR. Weiss Ratings cut X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Wells Fargo & Company began coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.